Results 131 to 140 of about 55,815 (216)

Anlotinib plus penpulimab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the perspective of the Chinese healthcare system. [PDF]

Front Oncol
Bai G, Yang H, Ge W, Yang R, Yu T, Qi R.
europepmc   +1 more source

Homeobox B13 activates the hypoxia-inducible factor 1 pathway through histone lactylation thereby reprogramming lipid metabolism and promoting sorafenib resistance in hepatocellular carcinoma. [PDF]

J Cell Commun Signal
Xie Q, Teng F, Ding T, Zhang H, Huang J, Zhang S.   +5 more
europepmc   +1 more source

Oligoprogressive renal cell carcinoma: What is the role of surgery?

BJU International, Volume 138, Issue 2, Page 219-228, August 2026.
Objective To provide an overview of the biological mechanism and pattern of oligoprogression in renal cell carcinoma (RCC) and the most updated role of surgery in this setting, highlighting scientific gaps and informing future implications. Methods A non‐systematic search of PubMed/MEDLINE was performed in August 2025 including guidelines, reviews, and
Chiara Re, William H.J. Ince, Leo Bickley, James P. Blackmur, Mouhamad H. Ismail, Justicia Kyeremeh, Teele Kuusk, Eva Mendes Serrao, James O. Jones, Grant D. Stewart   +9 more
wiley   +1 more source

The Antihistamine Astemizole Potentiates the Antitumor Efficacy of Sorafenib in Hepatocellular Carcinoma by Suppressing Proliferation, Metastasis, and Angiogenesis. [PDF]

Curr Issues Mol Biol
Zhang Y, Chen X, Yang X, Wang P, Zhang X, Kong D, Wang R.   +6 more
europepmc   +1 more source

RASD2 Drives Renal Clear Cell Carcinoma Progression via RAF1 (Ser338) Phosphorylation

Cancer Science, Volume 117, Issue 8, Page 2194-2207, August 2026.
RASD2 drives clear cell renal cell carcinoma (ccRCC) progression by physically interacting with RAF1 to induce its Ser338 phosphorylation, which subsequently activates the P38/ERK–MAPK signaling pathway to promote malignant tumor phenotypes and poor prognosis.
Jingxuan Yu, Gang Yu, Yuan Liu, Yu Zhou, Wei Liu, Lin Wang, Lide Liu, Yan Liu, Tiejun Pan, Zhenyu Liu, Lei Gao   +10 more
wiley   +1 more source

Astragaloside IV Reduces Sorafenib-Induced Cardiotoxicity by Inhibiting Apoptosis Through the STAT3/HIF-1α/Bcl-2 Signaling Pathway. [PDF]

Int J Mol Sci
Wang L, Liu B, You Q, Cai H, Huang T, Lei Y, Wang H, Yao Y, Shao S, Guo H.   +9 more
europepmc   +1 more source

MiR‐375 in CAFs‐Derived EVs Promotes HCC Progression via Regulating RASA1 and May Potentially Serve as a Biomarker for HCC

Cancer Science, Volume 117, Issue 8, Page 2208-2220, August 2026.
CAFs could transfer EVs miR‐375 into endothelial cells with a low level of RASA1 and further promote EC angiogenesis. Plasma EVs miR‐375 have the potential values as a novel diagnostic and prognostic biomarker for HCC. ABSTRACT Cancer‐associated fibroblasts (CAFs) in the tumor microenvironment play an important role in cancer initiation and progression
Wei Qin, Li Wang, Beiyuan Hu, Cuicui Xiao, XiaoYing Wu, Huan Tian, Songlin Peng   +6 more
wiley   +1 more source

(<i>E</i>)-4-(4-Acrylamidophenoxy)-<i>N</i>-Methylpicolinamides as b-Raf/VEGFR-2 Inhibitors with Antiangiogenic Activity in HUVEC and Zebrafish Model. [PDF]

Molecules
Velma GR, Telukutla SR, Vankudoth J, Grewal AS, Privér S, Yedla P, Akunuri R, Wlodkowic D, Pabbaraja S, Bhargava SK, Plebanski M, Kamal A.   +11 more
europepmc   +1 more source

Application of Systems Genetics to Investigate Molecular Pathology of Early‐Onset Colorectal Cancer

Chemical Biology &Drug Design, Volume 108, Issue 2, August 2026.
Early‐onset colorectal cancer (EOCRC) presents a complex molecular landscape that requires integrated multi‐omics approaches. This article reviews current applications of systems genetics in EOCRC research and provides a step‐by‐step protocol for network‐based analyses featuring PIK3CA to demonstrate practical application for researchers of all levels.
Minjae J. Kim, Sydney L. Carr, Vishnutheertha Kulkarni, Mary‐Louise Manchadi   +3 more
wiley   +1 more source

Advancing Systemic Treatment beyond First Line for Advanced Hepatocellular Carcinoma. [PDF]

Curr Oncol Rep
Wysocki PT, Chmiel P, Jassem J, Kraj L.
europepmc   +1 more source